Treatment success rate for patients treated for MDR-TB in Upper-middle income (World Bank)
Upper-middle income (World Bank): Treatment success rate for patients treated for MDR-TB was 66.0% in 2022. ▲ Rising
Latest (2022)
66.0%
Change on year
unchanged
Rank
9th
of 11 groups
All-time high
69.0%
in 2006
All-time low
48.0%
in 2009
Years of data
20
2002–2022
Treatment success rate for patients treated for MDR-TB in Upper-middle income (World Bank), 2002–2022
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for treatment success rate for patients treated for mdr-tb in Upper-middle income (World Bank) is 66.0%, measured in 2022.
The figure is up 24.5% over ten years.
Over the whole period, treatment success rate for patients treated for mdr-tb in Upper-middle income (World Bank) peaked at 69.0% in 2006 and was at its lowest, 48.0%, in 2009.
The long-run direction has been consistently rising across the 20 years of available data.
Treatment success rate for patients treated for MDR-TB in Upper-middle income (World Bank), year by year
| Year | Value | Change |
|---|---|---|
| 2002 | 50.0% | — |
| 2003 | 59.0% | +18.0% |
| 2004 | 60.0% | +1.7% |
| 2006 | 69.0% | +15.0% |
| 2007 | 50.0% | -27.5% |
| 2008 | 55.0% | +10.0% |
| 2009 | 48.0% | -12.7% |
| 2010 | 50.0% | +4.2% |
| 2011 | 53.0% | +6.0% |
| 2012 | 53.0% | +0.0% |
| 2013 | 52.0% | -1.9% |
| 2014 | 55.0% | +5.8% |
| 2015 | 56.0% | +1.8% |
| 2016 | 58.0% | +3.6% |
| 2017 | 59.0% | +1.7% |
| 2018 | 59.0% | +0.0% |
| 2019 | 60.0% | +1.7% |
| 2020 | 59.0% | -1.7% |
| 2021 | 66.0% | +11.9% |
| 2022 | 66.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 55.9% | 48.0% | 69.0% | 7 |
| 2010s | 55.5% | 50.0% | 60.0% | 10 |
| 2020s | 63.7% | 59.0% | 66.0% | 3 |
More health data for Upper-middle income (World Bank)
- Measles - number of reported cases, gaps filled 91,627 (2025)
- Diphtheria - number of reported cases, gaps filled 1,556 (2025)
- Total tetanus - number of reported cases, gaps filled 5,773 (2025)
- Pertussis - number of reported cases, gaps filled 63,803 (2025)
- Neonatal tetanus - number of reported cases, gaps filled 212 (2025)
- Number of under-five deaths, annual growth rate -6.19 % change on previous year (2024)
- Number of neonatal deaths, annual growth rate -4.24 % change on previous year (2024)
- Number of infant deaths, annual growth rate -4.78 % change on previous year (2024)
- Measles - number of reported cases, annual growth rate -27.52 % change on previous year (2025)
- Pertussis - number of reported cases, annual growth rate -87.69 % change on previous year (2025)
Frequently asked questions
- What is treatment success rate for patients treated for mdr-tb in Upper-middle income (World Bank)?
- Treatment success rate for patients treated for mdr-tb in Upper-middle income (World Bank) was 66.0% in 2022, according to World Health Organization, Global Health Observatory.
- What is the highest treatment success rate for patients treated for mdr-tb recorded in Upper-middle income (World Bank)?
- The highest recorded value was 69.0% in 2006.
- What is the lowest treatment success rate for patients treated for mdr-tb recorded in Upper-middle income (World Bank)?
- The lowest recorded value was 48.0% in 2009.
- How does Upper-middle income (World Bank) rank for treatment success rate for patients treated for mdr-tb?
- Upper-middle income (World Bank) ranks 9th out of 11 groups with data for 2022.
- Is treatment success rate for patients treated for mdr-tb rising or falling in Upper-middle income (World Bank)?
- Over the last ten years it is up 24.5%. The long-run trend across the full record is rising.
- Where does this Upper-middle income (World Bank) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Treatment success rate for patients treated for MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 20 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).